Business Context and Reporting Period
Company: Creative Medical Technology Holdings, Inc. (CELZ)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: A commercial-stage biotechnology company focused on regenerative therapies in immunotherapy, endocrinology, urology, neurology, and orthopedics. The company operates primarily through its subsidiary, Creative Medical Technologies, Inc. (CMT), and is developing multiple clinical programs including CELZ-201 for Type 1 Diabetes and chronic lower back pain, and the ImmCelz platform for immune disorders.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $6,000 | $11,000 |
| Cost of Goods Sold | $2,194 | $4,400 |
| Gross Profit | $3,806 | $6,600 |
| Operating Expenses | $6,146,620 | $5,750,461 |
| Operating Loss | $(6,142,814) | $(5,743,861) |
| Net Loss | $(5,995,008) | $(5,493,481) |
| Cash and Short-Term Investments | $7,208,126 | $5,940,402 |
| Working Capital | $7,114,134 | $5,807,659 |
| Net Cash Used in Operating Activities | $(5,856,445) | $(5,301,292) |
| Net Cash from Financing Activities | $7,174,666 | $1,454,636 |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 46% to $6,000 due to a reduction in sales of CaverStem kits. Management is re-evaluating marketing strategies for CaverStem and FemCelz.
- Increased Operating Loss: Operating loss increased by approximately $400,000 (7%) to $6.14 million, driven by a 16% increase in Selling, General, and Administrative (SG&A) expenses due to higher salaries, marketing costs, and insurance, partially offset by a 6% decrease in R&D expenses.
- Capital Raises: Significant cash inflows occurred through warrant exercise inducement transactions in March and October 2025, generating approximately $7.9 million in gross proceeds ($3.7 million and $4.2 million respectively), compared to $1.6 million from a registered direct offering in late 2024.
- Liquidity Improvement: Cash and short-term investments increased by approximately $1.27 million to $7.2 million, extending the company's runway.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Clinical Progress: The company completed patient enrollment for the ADAPT clinical trial (CELZ-201 for lower back pain) in December 2025. Initial data from the first cohort showed no serious adverse events and encouraging therapeutic potential. The FDA granted Fast Track designation to CELZ-201-DDT in August 2025.
- Strategic Partnerships: Expanded collaboration with Greenstone Biosciences Inc. to leverage AI for iPSC platform development and launched the BioDefense Veterans Initiative to address toxic burn pit exposure.
- Capital Needs: Management believes current cash reserves are sufficient to fund operations through at least March 2027. However, additional capital will be required to support ongoing clinical trials and commercialization efforts.
Risks and Contingencies
- History of Losses: The company has incurred significant operating losses and expects to continue doing so until product sales or licensing fees generate sufficient revenue.
- Regulatory Uncertainty: Success depends on FDA approval for key product candidates (e.g., ImmCelz, CELZ-201). Failure to obtain approval or delays in clinical trials could materially harm the business.
- Market Volatility: The stock price is highly volatile, and the company faces risks related to delisting from Nasdaq if it fails to meet continued listing requirements.
- Intellectual Property: Reliance on third-party patents and licenses (e.g., Jadi Cell, CMH) creates dependency risks and potential royalty obligations.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the $7.2 million cash balance and the projection that funds will last through March 2027 given the high burn rate (~$6M/year).
- Warrant Overhang: Review the terms of the 6.1 million outstanding warrants (weighted average exercise price ~$5.06) and the potential for future dilution from the new warrants issued in inducement transactions.
- Clinical Trial Data: Monitor the release of full data from the ADAPT trial (lower back pain) and the CREATE-1 trial (Type 1 Diabetes) to validate the "encouraging" preliminary results.
- Revenue Sustainability: Assess the viability of the CaverStem and FemCelz revenue streams, which generated only $6,000 in 2025, and the timeline for commercializing new therapies.
- Related Party Transactions: Review the terms of the Bionance LLC investment and the patent license agreements with related parties (CMH, Jadi Cell) for potential conflicts of interest or unfavorable terms.